The second day of of the conference will begin with opening remarks by NYSCF CEO Susan L.

Speakers include – : Harry Heimberg, Investigator, University of Brussels, Christopher Henderson, Co-Director, Motor Neuron Center at Columbia University, Michael A. Rudnicki, Director, Sprott Centre for Stem Cell Research, Ottawa Health Research Institute, Tom Okarma, president and CEO, Geron Corp, Amy Wagers, Assistant Professor of Stem Cell and Regenerative Biology, Joslin Diabetes Center, Harvard University and HSCI and Owen N. Director, Broad Center of Regenerative Medicine and Stem Cell Research.. The second day of of the conference will begin with opening remarks by NYSCF CEO Susan L. Solomon and welcome by Dr.

The conference opens on Tuesday 14 October with a day of panels designed for a wide audience. ,, ‘Road to the Clinic: From lab to therapy ‘is managed and moderated by Harvard Stem Cell Institute Director of Translational Medicine and NYSCF Scientific Advisor Lee Rubin, and will explore the process of acquisition of the research ‘from bench to the bedside. ‘Kevin Eggan, HSCI Principal Investigator and NYSCF Chief Scientific Officer, took the chair and moderate ‘Conference Preview: Research Highlights for a Lay Audience ‘, which the research will be presented and their deeper meaning preview. WNYC radio host Leonard Lopate moderate ‘The Political Landscape: What’s in Store? ‘a discussion exploring the ongoing public debate about stem cell research..Kiadis Pharma converted filing of IND, SPA inquiry and granted Orphan Drug Designation application with the FDA in the coming weeks. Cancer. Very pleased with the outcome which end of Phase II meeting with FDA and with the possibility to FDA Special Protocol Assessment program accessing happy conjunction with the strong support from our investigators we will is well prepared to a design clear path towards market approval on Reviroc ‘said Manja Bouman, CEO Kiadis Pharma.. The U.S. FDA get together follows the successful conclusion of a multicentre period II trials for Reviroc demonstrates improved survival after autologous bone marrow transplantation to non-Hodgkin’s lymphoma patient.

Equivalent Translation from third parties.. On RevirocReviroc has as a a treatment which eliminates the blood Krebs cells from autologous transplants for patients with end-stage blood cancer that develops. A autologous transplantation be used the patient is ‘s own bone marrow to serve as a graft. Bone marrow transplantation generally accepted as a treatment option of patients with blood cancers how leukemia and lymphoma. One of the limitations by autologous bone marrow transplantations be endorsed high rate of relapse using this treatment. This is often referred through the presence of cancerous cells in of transplantation and which the Patients Own white blood cells cause the fight against cancer. Reviroc is designed to residual tumor cells are removed from the graft. English available for available of Kiadis Pharma.

Random entries

Other entries from category "nephrology":